Infectious Disease
EBV Infection After Allogenic HSCT
1
Pipeline Programs↗
2
Active Trials↗
1
Companies Involved↗
EBV Infection After Allogenic HSCT is an early-stage landscape with 1 program across 1 company. The most active players are Roche.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Trial Status
2
clinical trials
Recruiting1 · 50%
Not yet recruiting1 · 50%
Clinical Trials
Trial Activity
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Recruiting·—·Phase 1·NCT06119256·12 enrolled
Prevention of Epstein-Barr Virus Reactivation With the ATG-based Haploidentical Protocol Combined With Rituximab in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial
Not yet recruiting·NNanfang Hospital, Southern Medical University·Preclinical·NCT07693881·106 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)